.jpeg)
{{ variable.name }}
Trelagliptin Succinate can delay the degradation of endogenous glucagon-like peptide-1 (GLP-1), thereby increasing the plasma concentration of active GLP-1.
1. Common name: Tretagliptin
2. Trade name: ZafatekTablets(ザファテック甭)
3. English name: b>Trelagliptin Succinate
4. Dosage form: Film-coated tablets
It is suitable for type 2 diabetes and needs to be used when blood sugar control is still unsatisfactory based on diet control and exercise therapy.
1. Specifications: 100mg/tablet (based on troagliptin)
2. Properties: 100mg: light red double-sided scored tablet, identification code D389, diameter approximately 11.0mm, thickness approximately 3.8mm.
Each tablet contains trotagliptin succinate which is equivalent to 100mg of trotagliptin
Adults usually take 100mg (calculated as trotagliptin) orally once a week. It is recommended to take it on the same day.
Patients with moderate or severe renal insufficiency need to adjust the dose:
Moderate (Ccr30–50mL/min): the dose is reduced to 50mg/week
Severe (Ccr<30mL/min) or end-stage renal disease: the dose is reduced to 25mg/week.
1. Before and after meals: It is recommended to take it 30 minutes before breakfast. Food has little impact on absorption.
2. Missed dose: If you forget to take the medicine, you should take it as soon as you remember. After that, you should still take the medicine on the original date. Do not double the dose.
3. Vomiting: If you vomit after taking the medicine, it is not recommended to take a supplement and you should wait for the next scheduled dose.
4. Others: Blood sugar needs to be monitored regularly. If the effect is not good after 2-3 months, adjustment of the treatment plan should be considered.
1. Renal insufficiency: The dose needs to be adjusted according to the creatinine clearance rate.
2. Hepatic insufficiency: Patients with moderate hepatic insufficiency do not need to adjust the dose.
3. Pregnant women: Use only when the benefits outweigh the risks.
4. Lactation period: It is recommended to weigh the necessity of breastfeeding and treatment.
5. Children: There is no clinical data and its use is not recommended.
6. Elderly people: Because renal function may decline, medication needs to be used with caution and adverse reactions monitored.
1. Common side effects (0.1–5%): Rash, itching, atrial fibrillation, elevated liver function indicators, elevated amylase, nasopharyngitis, etc.
2. Serious side effects: Hypoglycemia (especially in combination with sulfonylureas or insulin), acute pancreatitis, intestinal obstruction, and pemphigoid.
The following patients are contraindicated:
1. Severe ketosis, diabetic coma or type 1 diabetes;
2. Severe infection, perioperative period, severe trauma;
3. Those with a history of allergies to the ingredients of this product.
1. Combination with sulfonylureas and insulin may increase the risk of hypoglycemia, so dosage reduction needs to be considered;
2. Beta-blockers, salicylic acid preparations, etc. may enhance the hypoglycemic effect;
3. Epinephrine, corticosteroids, etc. may weaken the hypoglycemic effect.
Save at room temperature, avoid moisture and high temperatures.